Agios Pharmaceuticals Inc. (AGIO)

36.04
0.46 1.26
NASDAQ : Health Technology
Prev Close 36.50
Open 36.56
Day Low/High 35.97 / 37.04
52 Wk Low/High 33.17 / 79.17
Volume 438.73K
Avg Volume 562.30K
Exchange NASDAQ
Shares Outstanding 58.75M
Market Cap 2.15B
EPS -6.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Agios Announces Publication Of Data For Mitapivat From Core And Extension Phases Of The DRIVE PK Study In Patients With Pyruvate Kinase Deficiency In The New England Journal Of Medicine

Agios Announces Publication Of Data For Mitapivat From Core And Extension Phases Of The DRIVE PK Study In Patients With Pyruvate Kinase Deficiency In The New England Journal Of Medicine

-  Maximum Hemoglobin Increases >1.0 g/dL Observed in 50% of Patients in Core Period, Among Whom the Mean Maximum Hemoglobin Increase was 3.

Agios Reports Business Highlights And Second Quarter 2019 Financial Results

Agios Reports Business Highlights And Second Quarter 2019 Financial Results

Strong Topline Performance for IDH Inhibitors: TIBSOVO ® Net Revenue Increased 50% from Q1 2019 to $13.

Agios To Webcast Conference Call Of Second Quarter 2019 Financial Results On August 1, 2019

Agios To Webcast Conference Call Of Second Quarter 2019 Financial Results On August 1, 2019

CAMBRIDGE, Mass., July 18, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals Has Emerged From a 2-Year Base Pattern

Agios Pharmaceuticals Has Emerged From a 2-Year Base Pattern

Let's see if this new name is worth buying.

Watch Oncology Stocks Ahead of 2 Big Events

Watch Oncology Stocks Ahead of 2 Big Events

Data and industry conferences will likely be catalysts for shares in the space.

Newman Ferrara LLP Announces Corporate Governance Investigation Of Agios Pharmaceuticals Inc. - AGIO

Newman Ferrara LLP Announces Corporate Governance Investigation Of Agios Pharmaceuticals Inc. - AGIO

Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Agios Pharmaceuticals Inc.

TheStreet Quant Rating: D (Sell)